Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China.
Division of Life Science and Center for Chinese Medicine, The Hong Kong University of Science and Technology, Hong Kong, China.
Biomed Pharmacother. 2017 Oct;94:794-803. doi: 10.1016/j.biopha.2017.08.005. Epub 2017 Aug 10.
Hou-Po-Da-Huang Tang (HPDHT) was used for the treatment of intestinal tract diseases in China. However, the underlying mechanisms via the intestinal bacteria remain largely unclear. Therefore, the aim of this study was to evaluate the metabolism of HPDHT by the human intestinal bacteria and its modulating effect on the intestinal bacteria. As a result, a total of 34 compounds were identified in HPDHT and transformed HPDHT (T-HPDHT). Among them, 12 metabolites were proved to be transformed by human intestinal bacteria. In vitro assays showed that T-HPDHT exhibited more significant elevation of free radical scavenging activity and suppression on the production of nitric oxide (NO) and TNF-α when comparing to HPDHT. Additionally, in vivo experiment confirmed that HPDHT significantly increased activity of superoxide dismutase (SOD), attenuated the malondialdehyde (MDA) and TNF-α levels in the conventional rats compared with that of pseudo germ-free (PGF) rats. In addition, HPDHT could significantly enhance the mean counts of Bifidobacterium and Lactobacillus and inhibit the growth of Clostridium, and Enterobacteriaceae, relative to controls. Due to the transformation of HPDHT being dependent on the bacterial strain, the effect of HPDHT on the selective growth of Bifidobacterium bifidum 29521 and Lactobacillus plantarum 8014 was evaluated. The kinetic parameters of microbial growth and prebiotic activity scores indicated that HPDHT could selectively stimulate the growth of the strains Bifidobacterium bifidum 29521 and Lactobacillus plantarum 8014. Taken together, metabolism of HPDHT by intestinal bacteria is a critical step towards the emergence of their anti-oxidation, anti-inflammation and prebiotic activities. This study provided valuable information for further pharmacological research on HPDHT.
后朴大黄汤（HPDHT）在中国被用于治疗肠道疾病。然而，其通过肠道细菌发挥作用的具体机制仍不清楚。因此，本研究旨在评估 HPDHT 被人类肠道细菌代谢的情况及其对肠道细菌的调节作用。结果表明，在 HPDHT 和转化 HPDHT（T-HPDHT）中共鉴定出 34 种化合物。其中，有 12 种代谢物被证实是由人类肠道细菌转化而来的。体外实验表明，与 HPDHT 相比，T-HPDHT 表现出更高的自由基清除活性和对一氧化氮（NO）和肿瘤坏死因子-α（TNF-α）产生的抑制作用。此外，体内实验证实，与假无菌（PGF）大鼠相比，HPDHT 可显著提高普通大鼠超氧化物歧化酶（SOD）的活性，降低丙二醛（MDA）和 TNF-α水平。此外，与对照组相比，HPDHT 可显著增加双歧杆菌和乳酸杆菌的平均计数，抑制梭菌和肠杆菌科的生长。由于 HPDHT 的转化依赖于细菌株，因此评估了 HPDHT 对双歧杆菌双歧杆菌 29521 和植物乳杆菌 8014 选择性生长的影响。微生物生长的动力学参数和益生元活性评分表明，HPDHT 可以选择性地刺激双歧杆菌双歧杆菌 29521 和植物乳杆菌 8014 的生长。综上所述，肠道细菌对 HPDHT 的代谢是其抗氧化、抗炎和益生元活性出现的关键步骤。本研究为进一步研究 HPDHT 的药理学提供了有价值的信息。
